PURPOSE: Epithelial cellular adhesion molecule (EpCAM) is an attractive immunotherapeutic target to overcome metastasis of a variety of epithelium-oriented cancers. Edrecolomab, one kind of EpCAM monoclonal antibody (Panorex), has been approved for clinical application as postoperative adjuvant therapy in breast and colorectal cancer. However, the role of EpCAM in gastric cancer metastasis remains unclear. RESULTS: EpCAM was found to be more highly overexpressed in metastatic gastric cancer than in nonmetastatic samples by immunohistochemistry staining. The expression level of EpCAM in gastric cancer cell lines was determined by reverse-transcription polymerase chain reaction (RT-PCR) and Western blotting, respectively. Downregulation of EpCAM by small interfering RNA (siRNA) significantly suppressed in vitro adhesive, invasive, and migratory and in vivo metastatic abilities of gastric cancer cells. CONCLUSION: We provide first evidence that EpCAM contributes to the migration of gastric cancer, suggesting that EpCAM-targeted therapy might be a promising strategy in metastatic gastric cancer.
PURPOSE:Epithelial cellular adhesion molecule (EpCAM) is an attractive immunotherapeutic target to overcome metastasis of a variety of epithelium-oriented cancers. Edrecolomab, one kind of EpCAM monoclonal antibody (Panorex), has been approved for clinical application as postoperative adjuvant therapy in breast and colorectal cancer. However, the role of EpCAM in gastric cancer metastasis remains unclear. RESULTS:EpCAM was found to be more highly overexpressed in metastatic gastric cancer than in nonmetastatic samples by immunohistochemistry staining. The expression level of EpCAM in gastric cancer cell lines was determined by reverse-transcription polymerase chain reaction (RT-PCR) and Western blotting, respectively. Downregulation of EpCAM by small interfering RNA (siRNA) significantly suppressed in vitro adhesive, invasive, and migratory and in vivo metastatic abilities of gastric cancer cells. CONCLUSION: We provide first evidence that EpCAM contributes to the migration of gastric cancer, suggesting that EpCAM-targeted therapy might be a promising strategy in metastatic gastric cancer.
Authors: D G Huntsman; F Carneiro; F R Lewis; P M MacLeod; A Hayashi; K G Monaghan; R Maung; R Seruca; C E Jackson; C Caldas Journal: N Engl J Med Date: 2001-06-21 Impact factor: 91.245
Authors: Y Hippo; M Yashiro; M Ishii; H Taniguchi; S Tsutsumi; K Hirakawa; T Kodama; H Aburatani Journal: Cancer Res Date: 2001-02-01 Impact factor: 12.701
Authors: Markus Ladwein; Ulrich-Frank Pape; Dirk-Steffen Schmidt; Martina Schnölzer; Sabine Fiedler; Lutz Langbein; Werner W Franke; Gerhard Moldenhauer; Margot Zöller Journal: Exp Cell Res Date: 2005-10-01 Impact factor: 3.905
Authors: Na Liu; Feng Bi; Yanglin Pan; Lijun Sun; Yan Xue; Yongquan Shi; Xuebiao Yao; Yi Zheng; Daiming Fan Journal: Clin Cancer Res Date: 2004-09-15 Impact factor: 12.531
Authors: Bernardina T F van der Gun; Maria Maluszynska-Hoffman; Antal Kiss; Alice J Arendzen; Marcel H J Ruiters; Pamela M J McLaughlin; Elmar Weinhold; Marianne G Rots Journal: Bioconjug Chem Date: 2010-07-21 Impact factor: 4.774
Authors: Feride Kroepil; Agnieszka Dulian; Daniel Vallböhmer; Helene Geddert; Andreas Krieg; Christian Vay; Stefan A Topp; Jan Schulte am Esch; Stephan E Baldus; Olivier Gires; Wolfram T Knoefel; Nikolas H Stoecklein Journal: BMC Res Notes Date: 2013-07-05